{
    "Trade/Device Name(s)": [
        "ADVIA Chemistry Enzymatic Hemoglobin A1c (A1c_E) Assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K171771",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130255"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ",
        "LCP"
    ],
    "Summary Letter Date": "October 16, 2017",
    "Summary Letter Received Date": "October 17, 2017",
    "Submission Date": "November 29, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.1373",
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c Test System",
        "Glycosylated hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "hematology"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Whole blood",
        "Hemolysate"
    ],
    "Specimen Container(s)": [
        "Dipotassium EDTA tube",
        "Lithium Heparin tube",
        "Sodium Fluoride/Disodium EDTA tube",
        "Tripotassium EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA 1800 Clinical Chemistry System"
    ],
    "Method(s)/Technology(ies)": [
        "Quantitative enzymatic assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Siemens ADVIA Chemistry Enzymatic Hemoglobin A1c assay for quantitative determination of HbA1c in whole blood and hemolysate",
    "Indications for Use Summary": "In vitro diagnostic assay for quantitative determination of HbA1c (mmol/mol and %) in human anticoagulated venous whole blood and hemolysate to aid in diagnosis and monitoring of long-term blood glucose control in diabetes mellitus, and identification of patients at risk for developing diabetes mellitus",
    "fda_folder": "Clinical Chemistry"
}